Aziyo biologics reports second quarter 2023 financial results - transformation continues to drug-eluting biomatrix company

Negotiating multiple lois to divest orthopedic business cangaroo® rm 510(k) resubmission to the fda remains on track simpliderm® quarterly net sales up 32% year-over-year successful transfer of cardiovascular product distribution to lemaitre vascular silver spring, md., aug. 14, 2023 (globe newswire) -- aziyo biologics, inc. (nasdaq: azyo) (“aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today provided a business update and reported financial results for the second quarter ended june 30, 2023.
AZYO Ratings Summary
AZYO Quant Ranking